RGNX Quote, Financials, Valuation and Earnings

Edgewise Therapeutics has a net margin of -246.3% compared to Regenxbio's net margin of --. Regenxbio's return on equity of -69.62% beat Edgewise Therapeutics's return on equity of --.

Regenxbio has a consensus price target of $37.64, signalling upside risk potential of 393.27%. On the other hand Edgewise Therapeutics has an analysts' consensus of $49.43 which suggests that it could grow by 60.8%. Given that Regenxbio has higher upside potential than Edgewise Therapeutics, analysts believe Regenxbio is more attractive than Edgewise Therapeutics.

Regenxbio has a beta of 1.243, which suggesting that the stock is 24.251% more volatile than S&P 500. In comparison Edgewise Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regenxbio pays -- of its earnings as a dividend. Edgewise Therapeutics pays out -- of its earnings as a dividend.

Regenxbio quarterly revenues are $24.2M, which are larger than Edgewise Therapeutics quarterly revenues of --. Regenxbio's net income of -$59.6M is lower than Edgewise Therapeutics's net income of -$34.1M. Notably, Regenxbio's price-to-earnings ratio is -- while Edgewise Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 4.32x versus -- for Edgewise Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -246.3% compared to Regenxbio's net margin of 7.2%. Regenxbio's return on equity of -69.62% beat Sarepta Therapeutics's return on equity of 12.48%.

Regenxbio has a consensus price target of $37.64, signalling upside risk potential of 393.27%. On the other hand Sarepta Therapeutics has an analysts' consensus of $185.10 which suggests that it could grow by 55.59%. Given that Regenxbio has higher upside potential than Sarepta Therapeutics, analysts believe Regenxbio is more attractive than Sarepta Therapeutics.

Regenxbio has a beta of 1.243, which suggesting that the stock is 24.251% more volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.767, suggesting its less volatile than the S&P 500 by 23.328%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regenxbio pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Regenxbio quarterly revenues are $24.2M, which are smaller than Sarepta Therapeutics quarterly revenues of $467.2M. Regenxbio's net income of -$59.6M is lower than Sarepta Therapeutics's net income of $33.6M. Notably, Regenxbio's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 77.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 4.32x versus 7.30x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Entrada Therapeutics has a net margin of -246.3% compared to Regenxbio's net margin of -71.7%. Regenxbio's return on equity of -69.62% beat Entrada Therapeutics's return on equity of 17.06%.

Regenxbio has a consensus price target of $37.64, signalling upside risk potential of 393.27%. On the other hand Entrada Therapeutics has an analysts' consensus of -- which suggests that it could grow by 50.16%. Given that Regenxbio has higher upside potential than Entrada Therapeutics, analysts believe Regenxbio is more attractive than Entrada Therapeutics.

Regenxbio has a beta of 1.243, which suggesting that the stock is 24.251% more volatile than S&P 500. In comparison Entrada Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Entrada Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regenxbio pays -- of its earnings as a dividend. Entrada Therapeutics pays out -- of its earnings as a dividend.

Regenxbio quarterly revenues are $24.2M, which are larger than Entrada Therapeutics quarterly revenues of $19.6M. Regenxbio's net income of -$59.6M is lower than Entrada Therapeutics's net income of -$14M. Notably, Regenxbio's price-to-earnings ratio is -- while Entrada Therapeutics's PE ratio is 11.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 4.32x versus 2.95x for Entrada Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -246.3% compared to Regenxbio's net margin of 37.71%. Regenxbio's return on equity of -69.62% beat Vertex Pharmaceuticals's return on equity of -2.89%.

Regenxbio has a consensus price target of $37.64, signalling upside risk potential of 393.27%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $498.24 which suggests that it could grow by 25.42%. Given that Regenxbio has higher upside potential than Vertex Pharmaceuticals, analysts believe Regenxbio is more attractive than Vertex Pharmaceuticals.

Regenxbio has a beta of 1.243, which suggesting that the stock is 24.251% more volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.631%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regenxbio pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Regenxbio quarterly revenues are $24.2M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Regenxbio's net income of -$59.6M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Regenxbio's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 4.32x versus 9.73x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.